Canine T cell lymphoma treated with lomustine, vincristine, procarbazine, and prednisolone chemotherapy in 35 dogs

Canine T cell lymphoma has previously been found to be a poor prognostic indicator compared with its B cell counterpart. The cyclophosphamide, doxorubicin, vincristine, and prednisolone protocol is widely accepted as a first line treatment for canine lymphoma. There have been several studies investi...

Full description

Saved in:
Bibliographic Details
Published in:Veterinary & comparative oncology 2018-12, Vol.16 (4), p.622-629
Main Authors: Morgan, E., O'Connell, K., Thomson, M., Griffin, A.
Format: Article
Language:English
Subjects:
canine
chemotherapy
LOPP
oncology
T cell lymphoma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Canine T cell lymphoma has previously been found to be a poor prognostic indicator compared with its B cell counterpart. The cyclophosphamide, doxorubicin, vincristine, and prednisolone protocol is widely accepted as a first line treatment for canine lymphoma. There have been several studies investigating alternative protocols for T cell lymphoma. This study investigated the use of a modified lomustine, vincristine, procarbazine and prednisolone protocol as a first line treatment in 35 dogs with T Cell lymphoma. Median progression free survival (PFS) time for all 35 dogs was 431 days with a 6‐month, 1‐year, 2‐year, and 3‐year PFS of 69%, 54%, 29%, and 12%. Median survival time (MST) was 507 days. Twenty‐nine dogs attained a complete response and had a median PFS time of 509 days. Thirty dogs experienced adverse events during the protocol, with 73% of these being grade 1 or 2. This protocol has shown increased median PFS time and MST compared with previous studies and suggests its use as a first line chemotherapy protocol against canine T cell lymphoma.
ISSN:1476-5810
1476-5829
DOI:10.1111/vco.12430